Microparticles in Preeclampsia during Pregnancy: A Systematic Review and Meta-analysis

Background: Preeclampsia (PE) is a severe manifestation of maternal hypertensive disease with high morbidity and mortality which microparticles (MPs) might be generated. But there is limited evidence on response MPs with PE. Objectives: To explore the relationship between MPs and PE. Search strategy: A systematic review was performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines in Pubmed, Embase, Web of Science and China National Knowledge Infrastructure (inception to September 20, 2022). Selection criteria: Studies on patients diagnosed as PE were included. Studies on patients with chronic hypertension, pre-gestational diabetes mellitus, and history of recurrent pregnancy loss, renal or hepatic diseases, and antiphospholipid syndrome were excluded. Data collection and analysis: Two authors independently screened the studies, extracted the data and assessed the quality of the studies. Results were combined descriptively and analyzed using a standardized Excel form. Main results: We included 25 studies with a total of 1885 patients (862 with PE and 1023 with healthy pregnancy). Any MPs level was found no significant difference between PE and healthy pregnant patients in the second trimester. However, CD31-marked EMPs, RMPs and MPs from placenta are significantly elevated in the third trimester of preeclampsia, while CD41-marked PMPs is significantly decreased. After postpartum, tMPs and EMPs were found no significant difference between PE and healthy pregnant patients. Conclusion: MPs level is significantly associated with PE in the third trimester, but the association is dependent on its cell source and labeled marker.